SP SAP Drug Development

Toxicology studies with the potential chronic pain therapeutic, SP-SAP (Substance P-Saporin) are continuing successfully. The second study will be initiated in a few months and ATS is diligently pursuing a pharmaceutical partner that can quickly bring the drug to clinical trials in humans. With the recent news of the undesirable side effects of such pain […]

Chronic pain conditions are often caused by ongoing disease states or tissue damage that create sensitization of both the primary afferents (nerves that convey impulses from the outer part of the body) and spinal cord neurons. This sensitization results in a persistent increased sensitivity to both noxious (hyperalgesia) and non-noxious (allodynia) stimuli. Many persistent pain

Progress continues to be made in moving SP-SAP closer to clinical trials as a treatment for chronic pain. The latest development is the leasing of a 3700-sq ft facility adjacent to the current ATS facility in San Diego. This facility will be converted to GMP (Good Manufacturing Practice) space suitable for production of SP-SAP for

ATS has received a Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH) under the program announcement for competing continuation awards for pharmacologic agents and drugs for mental disorders. This three-year, $2.4 million award is a continuation of Phase II funding for the development of a drug for the treatment

Substance P-Saporin (SP-SAP) is under development as a chronic pain therapeutic with tremendous potential to permanently eliminate suffering in many painful diseases and conditions. ATS is awaiting news from the National Institutes of Health on further funding to fulfill FDA requirements to bring SP-SAP to clinical trial in humans. ATS has a patent on SP-SAP

On February 1, 2003 ATS was awarded an $800,000 grant from the National Institutes of Health, National Institute of Mental Health. This three-year grant will support the creation of monoclonal antibodies to the extracellular domains of G protein-coupled receptors. These receptors play an important role in all aspects of human health, reflecting their widespread presence

Advanced Targeting Systems continues to search for funding to develop Substance P-Saporin (SP-SAP) as a chronic pain therapeutic. In May of last year we decided to seek venture capital funding and began traveling to make presentations to potential investors. The response from most everyone we spoke to was positive and they thought the potential of

Early last month (March 2001), Advanced Targeting Systems (ATS) received funding from the National Institute of Mental Health (NIMH) to begin toxicology/safety studies of Substance P-Saporin (SP-SAP), a potential therapeutic for the treatment of chronic pain. The studies will be completed under the direction of three scientists who are experts in their respective fields. Dr.